Life science executives are invited to attend the 2nd Real World Evidence and Market Access Symposium being held as a virtual event on April 11-12, 2022. The event is hosted by DGE, a leading global event management company that caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, health care, medical devices, and allied industries.
The event centers around discussions, keynotes and sessions about the latest advances and best practices for harnessing real-world data insights that are productive for patients, payers and providers.
Organizations can strengthen their business and reimbursement strategies by identifying and accessing the correct data, as well as understanding how to leverage secondary data for greater efficiency in clinical trials. The first step involves identifying the relevant data that will eventually pave the path for providing the right kind of treatment to the patients. This high-quality data will prove pivotal in determining which line of treatment is approved, reimbursed and prescribed.
The forum will feature reputed dignitaries with excellent knowledge of RWE and how it can be used across a spectrum of clinical development, regulatory approval and access. The panelists will also share insights into how to ensure greater transparency in designing protocols, collect the right kind of data, and ensure its usefulness while addressing patient needs.
Some important topics to discuss include:
- Improve scientific communication and build value maps for specific patient demographics
- Collaborating data while working with electronic health records, medical claims and patient registries
- Learn how RWE is being utilized in oncology plus RWD and expanded access programs
- Hear from the experts about what to do and what not to do working with FDA
- Leverage the insights learned from RWD to make trials more inclusive and diverse
- Access the evolving RWE for COVID 19 treatments to inform critical decision making
The 2nd Real World Evidence and Market Access Symposium will witness stalwarts across a spectrum of fields including data analytics, regulatory affairs, world data, evidence platforms/solutions, trial management software, data management software, digital platform technology, CROs, artificial intelligence, and machine learning. Join this symposium to learn how to overcome the challenges faced in using RWE to complement and innovate clinical trials.
To learn more, please visit https://ibn.fm/SsROd.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.